KF
SUPN icon

Krilogy Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Krilogy Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,093
Closed -$55K – 602
2018
Q3 		$55K Buy
+1,093
New +$54K 0.01% 302
2018
Q2 		– Sell
-954
Closed -$44K – 561
2018
Q1 		$44K Hold
954
– – 0.01% 343
2017
Q4 		$38K Hold
954
– – 0.01% 355
2017
Q3 		$38K Hold
954
– – 0.01% 385
2017
Q2 		$41K Buy
+954
New +$34K 0.01% 334

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Krilogy Financial's SUPN Position: Q4 2018 in Review

Krilogy Financial sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 1,093 shares — an estimated $55K sold.

Krilogy Financial first reported a position in SUPN in Q2 2017 and held it in 5 quarters. The position peaked at $55K in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Krilogy Financial reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 1,093 Supernus Pharmaceuticals shares in Q4 2018, an estimated $55K.
  • Krilogy Financial first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 5 quarters.
  • Krilogy Financial's Supernus Pharmaceuticals position peaked at $55K in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.